Eight new drugs have been approved for market in China, with three of them for cancer treatment! They are from companies such as Johnson & Johnson (JNJ.US) and FOSUN PHARMA (02196).
According to the official website of the China National Medical Products Administration (NMPA) and public information, at least 8 new drugs have been approved for sale in China in February 2025.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
The affiliated payment company, Shanmeng Technology, has reduced its capital, and the past financial territory of the Fosun Group has already contracted.
① The registered capital of Zhejiang Business Alliance Technology Co., Ltd. under the "Fosun Group" has decreased by 5.298 million yuan, and at the same time, the company's second largest Shareholder has withdrawn. ② In recent years, the "Fosun Group" has been continuously shrinking its capital territory, with the total debt-to-capital ratio maintaining a downward trend since 2020.
Fosun collaborates with ADIO to promote the expansion of its subsidiaries' Business into Abu Dhabi and the Middle East.
① FOSUN INTL has signed a memorandum of strategic cooperation with the Abu Dhabi Investment Office, aiming to promote the expansion of its subsidiaries into Abu Dhabi and the broader Middle East region; ② FOSUN INTL's FOSUN Wealth Holdings and Starway Technology are actively engaging with related Institutions in the Middle East to explore cooperation opportunities in wealth management and CNI Xiangmi Lake Fintech Index.
It was reported that FOSUN PHARMA will sell its Indian pharmaceutical company, and it stated that it will continue to promote the development of the Indian company in the Global market.
① It is rumored that FOSUN PHARMA will sell its pharmaceutical company Gland Pharma located in India, and the company stated it will continue to promote Gland Pharma's development and growth in the Global market. ② Previously, FOSUN PHARMA had reduced its Shareholding in Gland Pharma to supplement working capital, repay interest-bearing debts, and so on.
Heparin centralized procurement not being selected has affected product sales. Hebei Changshan Biochemical Pharmaceutical expects a net loss in 2024 | Quick read announcement.
In 2024, Hebei Changshan Biochemical Pharmaceutical is expected to continue to report a loss in net income, but with a significant narrowing compared to 2023; previously, the company stated that there are currently no plans to conduct clinical trials for the weight loss indication of Abengutai injection.